Research & Advocacy
Research, Advocacy & Community
Supporting awareness, participation and a stronger amyloidosis community.
Understanding treatment options, supportive care and how specialists make a personalized plan for different forms of amyloidosis.
Amyloidosis is a group of disorders caused by amyloid protein deposits. Treatment depends on the exact amyloid protein, organs involved, disease severity and a patient's overall health.
Core treatment goal: reduce or prevent further amyloid formation, protect affected organs, relieve symptoms and monitor how treatment is working. A specialist team should confirm the amyloid type before choosing disease-specific therapy. Treatment may control disease, but it does not reliably reverse all existing organ damage.
Your medical team may include a hematologist, cardiologist, nephrologist, neurologist and other specialists, depending on the organs involved.
Review pathology, protein typing and other relevant investigations to distinguish AL, ATTR, AA or another form.
Check heart, kidney, nerve and other organ involvement to understand the risks and choose suitable therapy.
Start appropriate care and review symptoms, blood markers, organ function and treatment side effects over time.
The examples below describe treatment categories, not prescriptions. Options and access vary by country, clinical indication and individual assessment.
Specialists aim to rapidly suppress abnormal plasma cells that produce harmful light chains.
AL therapy needs specialist hematology supervision and close monitoring.
Treatment may slow formation of transthyretin amyloid or reduce production of the TTR protein.
Eligibility, availability and approvals depend on indication and location.
The priority is control of the chronic inflammatory or infectious condition driving excess serum amyloid A production.
The exact approach varies with the underlying disease.
Care is guided by the site of deposits and the mechanism causing amyloid accumulation.
Evaluation must distinguish localized from systemic disease.
Controlling amyloid production is only one part of care. Symptoms and organ complications also need attention.
Clinicians may manage swelling, fluid balance, heart rhythm issues and low blood pressure. Some conventional heart medicines require special caution in amyloidosis.
Monitoring kidney tests, urine protein and swelling can guide treatment. Advanced kidney disease may require dialysis or specialist transplant evaluation.
Nutrition advice, symptom relief, safe activity, medication review, counselling and regular follow-up may help with quality of life.
Helpful starting points for a discussion with your medical team.
There is no single cure for every form of amyloidosis. Many treatments can slow or suppress amyloid formation, control symptoms and reduce the chance of further organ damage. Results vary by type and individual condition.
AL, ATTR, AA and other forms involve different proteins and require different treatment strategies. Choosing the wrong approach may delay effective care.
No. A transplant is an option only for carefully selected patients. Many receive medicine-based regimens instead, based on organ function and overall health.
ATTR medicines primarily aim to slow disease progression; improvement varies, and existing damage may not be reversible. Your cardiology team can explain realistic expectations.
Doctors may review symptoms, blood tests, serum free light chains where relevant, heart or kidney markers, imaging and treatment side effects, depending on the amyloidosis type.
Ask your medical team which amyloid protein was identified, what organs are involved and how treatment response will be monitored. ASGI supports awareness and patient education.
Medical information notice: This page is for education only and does not replace advice from a qualified healthcare professional. Individual treatment options, medicine approvals and availability may differ.
Further reading: Mayo Clinic — AL treatment · Mayo Clinic — Cardiac amyloidosis · NHS — Amyloidosis
